NASDAQ:DNLI Denali Therapeutics Q2 2026 Earnings Report $23.85 -0.20 (-0.83%) Closing price 04:00 PM EasternExtended Trading$24.15 +0.30 (+1.26%) As of 07:59 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. ProfileEarnings HistoryForecast Denali Therapeutics EPS ResultsActual EPSN/AConsensus EPS -$0.54Beat/MissN/AOne Year Ago EPSN/ADenali Therapeutics Revenue ResultsActual RevenueN/AExpected Revenue$2.15 millionBeat/MissN/AYoY Revenue GrowthN/ADenali Therapeutics Announcement DetailsQuarterQ2 2026Date8/6/2026TimeBefore Market OpensConference Call DateThursday, August 6, 2026Conference Call Time4:30PM ETConference Call ResourcesEarnings HistoryCompany Profile Denali Therapeutics Earnings HeadlinesDenali Therapeutics to Report Second Quarter 2026 Financial Results and Business Highlights on August 6, 2026July 27 at 4:01 PM | globenewswire.comGoldman Sachs Remains a Buy on Denali Therapeutics (DNLI)July 23, 2026 | theglobeandmail.comALERT: Drop these 5 stocks before the market opens tomorrow!The Wall Street Journal is already raising the alarm about a potential market crash, and Weiss Ratings research points to the first half of 2026 as a particularly rough stretch for certain holdings. Some of America's most popular stocks could take serious damage as a radical market shift plays out. Analysts at Weiss Ratings have identified five names you may want to remove from your portfolio before this unfolds. If any of these are in your portfolio, now is the time to review your positions.July 29 at 1:00 AM | Weiss Ratings (Ad)Is Denali Therapeutics (DNLI) Overvalued After Its FDA Approval?July 23, 2026 | finance.yahoo.comDenali Therapeutics (DNLI) Heads To AAIC, Is The Stock Already Pricey?July 23, 2026 | finance.yahoo.comDenali Therapeutics to Give Opening Plenary Address at Alzheimer’s Association International Conference (AAIC) 2026 and Highlight Breakthroughs in Delivering Biologic ...July 9, 2026 | markets.businessinsider.comSee More Denali Therapeutics Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Denali Therapeutics? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Denali Therapeutics and other key companies, straight to your email. Email Address About Denali TherapeuticsDenali Therapeutics (NASDAQ:DNLI) is a clinical‐stage biopharmaceutical company focused on developing therapies for neurodegenerative diseases. The company’s research leverages a proprietary Blood–Brain Barrier Transport Vehicle (TV) platform designed to enable large molecules, including antibodies and enzymes, to penetrate the central nervous system. Denali’s approach includes small molecules, monoclonal antibodies and gene therapy candidates aimed at key drivers of disorders such as Alzheimer’s disease, Parkinson’s disease, amyotrophic lateral sclerosis (ALS) and frontotemporal dementia. Among Denali’s lead programs is an orally delivered leucine‐rich repeat kinase 2 (LRRK2) inhibitor for Parkinson’s disease, and an anti‐TREM2 antibody designed to modulate microglial activity in Alzheimer’s patients. The company is also advancing modulators of progranulin for frontotemporal dementia and exploring novel approaches to lysosomal storage disorders. Denali has entered strategic collaborations with established industry partners to accelerate clinical development, most notably with Biogen for Alzheimer’s and Sanofi for lysosomal programs. Founded in 2015 by industry veteran Stefan Oehlén and headquartered in South San Francisco, Denali maintains research sites in Cambridge, Massachusetts, and has expanded its organization to support global clinical trials. The company went public in 2019, and its leadership is led by Chief Executive Officer Ryan Watts, whose background in finance and biotech supports Denali’s capital strategy and pipeline advancement. Denali Therapeutics conducts its research and clinical operations primarily in the United States while pursuing regulatory approvals and trial sites globally. The company’s goal is to address unmet needs in neurodegeneration by bringing forward differentiated therapies that can slow or stop disease progression, offering new hope for patients and families affected by these challenging disorders.View Denali Therapeutics ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles Why SK hynix Could Be the Best AI Chip Stock to Buy NowWhy Bloom Energy May Be the Most Important AI Infrastructure StockAlphabet Is Down 18% From Its High After a Stellar Quarter—Overdone, or More Downside Ahead?Seagate Technology Stock Surges as Earnings Beat Silences AI DoubtersCarrier Earnings Could Send the Stock to a New All-Time High3 Refiners Benefiting From Oil Volatility and Tight Fuel SupplyWelltower at 52-Week Highs—But Analysts Believe There's More to Come Upcoming Earnings Ferrari (7/30/2026)Air Products and Chemicals (7/30/2026)ArcelorMittal (7/30/2026)Vale (7/30/2026)Mastercard (7/30/2026)Apple (7/30/2026)ASE Technology (7/30/2026)Monolithic Power Systems (7/30/2026)CRH (7/30/2026)Quanta Services (7/30/2026) Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
